Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical…
0,550€
10,89%
Echtzeit-Aktienkurs CONTEXT THERAPEUT.DL-,001
Bid:
Ask:
Nachrichten zur CONTEXT THERAPEUT.DL-,001 Aktie
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage…
Bet on These 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc,…
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX),…
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical…
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company…
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody…